By Counterforce Health Team in Elaprase (idursulfase) —

How to Get Elaprase (Idursulfase) Covered by Blue Cross Blue Shield in New Jersey: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Started Today

To get Elaprase (idursulfase) covered by Blue Cross Blue Shield in New Jersey: You'll need prior authorization with both enzymatic and genetic confirmation of Hunter syndrome (MPS II), weight-based dosing documentation, and an infusion monitoring plan. Submit through Horizon BCBS provider portal or Prime Therapeutics at 1-888-214-1784. Standard review takes up to 72 hours; urgent cases within 24-72 hours. If denied, you have 120 days to appeal internally, then can request external review through New Jersey's IHCAP program administered by Maximus Federal Services.

Start today: Call your Blue Cross Blue Shield member services (number on your ID card) to verify Elaprase coverage and confirm which specialty pharmacy is in-network.

Table of Contents

  1. What This Guide Covers
  2. Before You Start: Verify Your Coverage
  3. Gather Required Documentation
  4. Submit Your Prior Authorization Request
  5. Follow-Up and Timeline Management
  6. If You're Asked for More Information
  7. If Your Request Is Denied
  8. New Jersey External Appeals (IHCAP)
  9. Renewal and Reauthorization
  10. Quick Reference Checklist

What This Guide Covers

This guide helps patients with Hunter syndrome (MPS II) and their healthcare providers navigate Blue Cross Blue Shield prior authorization and appeals for Elaprase (idursulfase) in New Jersey. We'll walk through the specific requirements, forms, timelines, and appeal processes—including New Jersey's robust external review system.

Hunter syndrome is a rare genetic disorder requiring lifelong enzyme replacement therapy. Elaprase, manufactured by Takeda, is the only FDA-approved treatment, making insurance coverage critical for accessing this life-sustaining medication that can cost over $300,000 annually.

From Our Advocates: We've seen families succeed by being proactive with documentation. One New Jersey family gathered all required testing results before their first appointment, which helped their provider submit a complete prior authorization package immediately. While outcomes vary, thorough preparation often leads to faster approvals.

Before You Start: Verify Your Coverage

Step 1: Confirm Your Plan Type

Contact Blue Cross Blue Shield member services (number on your insurance card) to verify:

  • Whether you have Horizon Blue Cross Blue Shield of New Jersey or another Blue plan
  • If Elaprase requires prior authorization under your specific plan
  • Which specialty pharmacy network you must use (typically Accredo)

Step 2: Check Medical vs. Pharmacy Benefit

Elaprase is typically covered under the medical benefit since it requires IV infusion. Confirm:

  • Your medical benefit deductible and coinsurance
  • Whether home infusion or hospital-based infusion is preferred
  • In-network infusion centers near you

Step 3: Verify Formulary Status

While Elaprase has no FDA-approved alternatives for Hunter syndrome, some plans may have specific coverage criteria. Ask about:

  • Formulary tier placement
  • Any quantity limits based on weight
  • Step therapy requirements (unlikely but possible)

Gather Required Documentation

Blue Cross Blue Shield requires comprehensive clinical documentation for Elaprase approval:

Essential Medical Records

  • Hunter syndrome diagnosis confirmation:
    • Enzymatic testing showing iduronate-2-sulfatase (I2S) deficiency
    • Genetic testing confirming pathogenic IDS gene mutation
  • Current weight for accurate dosing calculations (0.5 mg/kg weekly)
  • Clinical notes documenting MPS II symptoms and progression
  • ICD-10 codes: E76.1 (Mucopolysaccharidosis, type II)

Specialist Documentation

  • Prescription from a physician experienced in treating MPS II
  • Infusion monitoring plan including:
    • Pre-medication protocols
    • Vital sign monitoring schedule
    • Emergency response procedures for infusion reactions
  • Treatment goals and expected outcomes

Prior Authorization Forms

Access current PA forms through:

Submit Your Prior Authorization Request

Submission Methods

Online: Horizon BCBS provider portal (fastest) Phone: Prime Clinical Review at 1-888-214-1784 Fax: Check current fax number on PA form (verify with source)

Clean Request Packet Checklist

✅ Completed PA form with all required fields ✅ Enzymatic test results showing I2S deficiency ✅ Genetic testing confirming IDS mutation ✅ Current weight and dosing calculation ✅ Detailed infusion monitoring plan ✅ Specialist prescription and clinical notes ✅ ICD-10 diagnosis code (E76.1) ✅ Previous treatment history (if applicable)

Specialty Pharmacy Coordination

Once approved, Elaprase is typically dispensed through Blue Cross Blue Shield's contracted specialty pharmacy network. Ensure your provider coordinates with:

  • Accredo (most common specialty pharmacy)
  • Approved infusion centers
  • Home healthcare providers (if applicable)

Follow-Up and Timeline Management

New Jersey Mandated Timelines

  • Urgent requests: 24-72 hours
  • Standard requests: Up to 72 hours (some plans allow up to 15 calendar days)
  • Appeals: 120 days from denial notice

When to Call

  • Day 3: If no acknowledgment received
  • Day 5: If no decision rendered for urgent requests
  • Day 10: If no decision for standard requests

Sample Follow-Up Script

"Hello, I'm calling to check the status of a prior authorization request for Elaprase submitted on [date]. The reference number is [if available]. This is for Hunter syndrome, a rare genetic condition requiring urgent treatment. Can you provide an update and expected timeline?"

If You're Asked for More Information

Common Medical Necessity Questions

"Why is this medication necessary?"

  • Hunter syndrome is a progressive, life-threatening genetic disorder
  • Elaprase is the only FDA-approved enzyme replacement therapy
  • Without treatment, patients experience multi-organ deterioration

"Are there alternatives?"

  • No FDA-approved alternatives exist for Hunter syndrome
  • Supportive care alone cannot address the underlying enzyme deficiency
  • Early treatment is critical to prevent irreversible organ damage

Additional Documentation

Be prepared to provide:

  • Recent cardiac evaluation (echocardiogram, ECG)
  • Pulmonary function tests
  • Growth charts (for pediatric patients)
  • Peer-reviewed literature supporting treatment

If Your Request Is Denied

Common Denial Reasons and Solutions

Denial Reason Solution
Missing enzymatic testing Submit I2S enzyme activity results
Incomplete genetic confirmation Provide IDS gene mutation analysis
Inadequate monitoring plan Detail infusion protocols and emergency procedures
Dosing outside guidelines Justify weight-based calculations with current weight
Non-specialist prescriber Transfer care to MPS specialist or obtain consultation

Internal Appeals Process

  1. First-level appeal: Submit within 120 days of denial
  2. Include new evidence: Address specific denial reasons
  3. Request peer-to-peer review: Have your specialist speak with Blue Cross Blue Shield medical director
  4. Expedited appeals: Available if delay could cause serious harm

Appeal Documentation

  • Original denial letter
  • Point-by-point rebuttal addressing denial reasons
  • Additional clinical evidence
  • Peer-reviewed literature on Hunter syndrome
  • Specialist letter emphasizing medical necessity

New Jersey External Appeals (IHCAP)

If Blue Cross Blue Shield upholds their denial after internal appeals, New Jersey offers one of the nation's strongest external review programs.

IHCAP Process Overview

New Jersey's Independent Health Care Appeals Program is administered by Maximus Federal Services and provides independent medical review by specialists.

Eligibility Requirements

  • Completed internal appeals process with Blue Cross Blue Shield
  • Denial based on medical necessity or similar clinical grounds
  • Fully-insured plan regulated by New Jersey

Filing Timeline

  • Standard cases: 4 months from final internal denial
  • Expedited cases: Available if delay risks serious harm
  • Medicaid/NJ FamilyCare: 60 days from denial

How to File

Contact: Maximus Federal Services Address: 3750 Monroe Avenue, Suite 705, Pittsford, NY 14534 Fax: 585-425-5296 Email: [email protected] Phone: 1-888-393-1062

IHCAP Decision Timeline

  • Expedited appeals: 48 hours from complete submission
  • Standard appeals: 45 calendar days
  • Cost: Free to patients (insurers pay all fees)

What to Include

  • Complete medical records
  • Denial letters from Blue Cross Blue Shield
  • Specialist opinions on medical necessity
  • Clinical literature supporting treatment
  • Statement of why delay would cause harm (for expedited review)

Renewal and Reauthorization

Annual Review Requirements

Most Blue Cross Blue Shield plans require annual reauthorization for Elaprase, typically including:

  • Updated weight and dosing calculations
  • Clinical response documentation
  • Continued specialist oversight
  • Infusion tolerance assessment

Evidence of Clinical Response

Document improvements or stabilization in:

  • Organ size (liver, spleen via imaging)
  • Respiratory function
  • Physical endurance and mobility
  • Quality of life measures

Calendar Reminders

Set reminders 60-90 days before authorization expires to begin renewal process early and prevent treatment interruptions.

Quick Reference Checklist

Before Calling Blue Cross Blue Shield

  • Insurance card and member ID ready
  • Policy group number
  • Prescribing physician information
  • Current weight and calculated dose
  • Diagnosis confirmation (Hunter syndrome/MPS II)

Required Documentation

  • Enzymatic testing (I2S deficiency)
  • Genetic testing (IDS mutation)
  • Specialist prescription
  • Infusion monitoring plan
  • Clinical notes and ICD-10 code

If Denied

  • Request written denial with specific reasons
  • File internal appeal within 120 days
  • Consider peer-to-peer review
  • Prepare for IHCAP external appeal if needed

Counterforce Health specializes in turning insurance denials into successful appeals for specialty medications like Elaprase. Our platform analyzes denial letters and plan policies to create targeted, evidence-backed appeals that align with insurers' own rules. By pulling the right clinical evidence—FDA labeling, peer-reviewed studies, and specialty guidelines—we help patients and providers build stronger cases for coverage approval.

For additional support navigating Blue Cross Blue Shield coverage challenges, visit www.counterforcehealth.org to learn how our targeted approach can help secure the medications you need.

Takeda Patient Support Programs

Takeda offers comprehensive support through their OnePath program:

  • Insurance coverage assistance and prior authorization support
  • Co-pay assistance for eligible patients
  • Uninsured patient access programs
  • Care coordination between providers and specialty pharmacies

Contact OnePath: Visit elaprase.com or call the support line for enrollment and case management services.

When to Escalate

If you experience unreasonable delays or denials, consider contacting:

  • New Jersey Department of Banking and Insurance: 1-800-446-7467
  • IHCAP Hotline: 1-888-393-1062
  • Takeda OnePath: For manufacturer advocacy support

Sources & Further Reading

Disclaimer: This guide provides general information about insurance coverage and appeals processes. It is not medical advice and does not guarantee coverage approval. Always consult with your healthcare provider about treatment decisions and verify current insurance requirements with your plan. Coverage policies and procedures may change; confirm details with official sources before taking action.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.